$HNGE

Budge James sold $187K of HNGE

Budge James (Chief Financial Officer) sold 3,507 shares of Hinge Health, Inc. (HNGE) at $53.32 ($0.19M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Budge James
Published May 27, 2026, 11:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HNGE
Neutral
high confidence
Mentioned
$HNGE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not, by itself, indicate a change in business outlook or near-term catalysts.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 designation makes this more of a routine compliance update than a fundamental signal.

03

What to watch

Insider sales can be driven by diversification/tax planning; without additional filings (e.g., large buys, option exercises, or changes in guidance), signal quality is low.

Relevance 6/10Timing: Immediate (filed today) but informationally routine; any trading effect is likely short-lived.

Background

The article is an SEC Form 4 disclosure showing an officer’s open-market sale of Hinge Health shares, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$HNGENeutralHigh confidence
Context

Hinge Health CFO Budge James sold $187,006 of HNGE shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a declared 10b5-1 plan, providing less signal about new fundamentals.

Market effects

Minimal; insider Form 4s typically do not reset sector expectations for healthcare/telehealth names.

None indicated.

None indicated.

Counterpoint

If the market overreacts to insider selling, the 10b5-1 structure suggests the move may not reflect bearish fundamentals, creating a potential mean-reversion opportunity.

Key entities

  • Hinge Health, Inc.

    Subject of the Form 4 insider transaction; CFO Budge James sold shares under a 10b5-1 plan.

  • Budge James

    Chief Financial Officer who executed the reported sale.

Related articles

$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.